XIENCE Skypoint Large Vessel Post Approval Study

Active, not recruitingOBSERVATIONAL
Enrollment

102

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

August 30, 2025

Study Completion Date

August 30, 2027

Conditions
Coronary Artery Disease
Interventions
DEVICE

XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS)

XIENCE Skypoint Large Vessel EECSS is composed of a L-605 CoCr stent and coated with poly (n-butyl methacrylate) (PBMA) primer and a drug coating formulation of polymer of vinylidene fluoride and hexafluoropropylene (PVDF-HFP)/everolimus pre-mounted on a balloon catheter delivery system.

Trial Locations (18)

10075

Lenox Hill Hospital, New York

17043

Pinnacle Health System, Wormleysburg

29621

Anmed Health, Anderson

31300

Clinique Pasteur Toulouse, Toulouse

32216

Memorial Hospital Jacksonville, Jacksonville

32308

Tallahassee Research Institute, Tallahassee

67226

Via Christi Regional Medical Center - St. Francis Campus, Wichita

68506

Bryan Heart, Lincoln

72211

Arkansas Heart Hospital, Little Rock

75074

The Heart Hospital Baylor Plano, Plano

76903

Shannon Clinic, San Angelo

78756

Austin Heart, Austin

79601

Hendrick Medical Center, Abilene

29605-5601

Greenville Health System, Greenville

Unknown

Hopital Cardiovasculaire et Pneumologique Louis Pradel, Lyon

Hospital Clinico San Carlos, Madrid

Hospital Universitario Marqués de Valdecilla, Santander

Hospital Virgen de Rocio, Seville

Sponsors
All Listed Sponsors
lead

Abbott Medical Devices

INDUSTRY